Special Issue

Frontiers in Chronic Kidney Disease

Message from the Guest Editor

Chronic kidney disease is one of the most important risk factors for end-stage kidney disease. The number of chronic kidney disease patients is increasing, especially with age. The optimal strategy to prevent the progression of chronic kidney disease is an urgent question worldwide that remains unanswered. This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of the science and showcase some of the latest findings in the field of chronic kidney disease. We seek studies, including those that explore any conditions related to chronic kidney disease, using basic science, clinical and population-based approaches, as well as all kinds of behaviors for public awareness. Scientific advances in the field of chronic kidney disease will provide the promise of a more optimistic future for patients.

Guest Editor

Prof. Dr. Haruhito A. Uchida

Department of Chronic Kidney Disease and Cardiovascular Disease, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Deadline for manuscript submissions

closed (25 September 2022)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/83850

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

